Kilitch Drugs Begins Operations at New Nutraceutical Facility; Shares Ease

Mumbai, June 17: Kilitch Drugs (India) Ltd announced the commencement of its nutraceutical manufacturing block at the company’s new plant in Maharashtra, marking a fresh capacity addition as it expands its presence in the healthcare and wellness segment.

In an exchange filing, the company said the nutraceutical manufacturing block located at village Maldev, Taluka Pen, district Raigad, Maharashtra, became operational today.

The announcement represents a key milestone in the commissioning of Kilitch’s new manufacturing facility. While the company did not disclose the investment amount, production capacity, or expected revenue contribution, the start of commercial operations signals that the facility has moved from the development phase to active manufacturing.

The nutraceutical industry has emerged as one of the fastest-growing segments within healthcare, driven by increasing consumer focus on preventive healthcare, dietary supplements and wellness products. The new block is expected to strengthen Kilitch’s manufacturing footprint in this growing market.

Stock Market Snapshot

Despite the operational milestone, investor reaction remained subdued.

As of 2:23 PM IST on June 17, 2026, Kilitch Drugs shares were trading at ₹184.50, down 0.55% from the previous close.

The Kilitch Drugs share price remained under pressure through most of the trading session, suggesting that the commencement of the facility had largely been anticipated by the market or was overshadowed by broader market factors.

Investors often look for additional details such as capacity utilisation, revenue potential, order visibility and margin contribution before assigning significant valuation premiums to manufacturing expansions.

Expansion Reflects Focus on Growth Segments

The commissioning of the nutraceutical block comes at a time when pharmaceutical companies are increasingly diversifying into wellness and nutrition-focused products.

Nutraceuticals have become an attractive segment due to rising health awareness, expanding distribution channels and growing demand for preventive healthcare solutions. Manufacturers with dedicated production facilities can benefit from greater operational flexibility and faster product development cycles.

For Kilitch, the operationalisation of the new block could provide additional manufacturing capabilities and support future growth initiatives in both domestic and export markets.

About Kilitch Drugs

Kilitch Drugs (India) Ltd is engaged in the manufacture and marketing of pharmaceutical formulations and healthcare products. The company has a presence across multiple therapeutic categories and serves domestic as well as international markets.

Over the years, Kilitch has expanded its product portfolio and manufacturing infrastructure to cater to evolving healthcare demand. The addition of a dedicated nutraceutical manufacturing block aligns with the industry’s increasing focus on wellness-oriented products.

Conclusion

The commencement of Kilitch Drugs’ new nutraceutical manufacturing block marks an important operational milestone and strengthens the company’s manufacturing base in Maharashtra.

While the stock traded modestly lower on June 17, the facility provides the company with additional production capacity in a fast-growing segment. Investors are likely to watch for further disclosures on capacity utilisation, product launches and the financial contribution of the new unit in the coming quarters.

Source:

• https://www.nseindia.com/get-quote/equity/KILITCH/Kilitch-Drugs-(India)-Limited
• https://nsearchives.nseindia.com/corporate/KILITCH_17062026140834_IntimationToStockExchanges.pdf